Atopic Dermatitis
Conditions
Interventions
Trade Name: Emend
Product Name: Emend
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Emend
CAS Number: 170729-80-3
Current Sponsor code: 1001
Other descriptive name: APREPITANT
Concentration
Sponsors
Karolinska Institutet
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Ongoing atopic dermatitis (diagnosted by dermatologist, Williams criteria). - Moderate to severe disease (SCORAD > 20). - Local treatment have not given sufficient effect. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Age over 40 or under 20 years - Skin infection - Other sytemic treatment for the atopic dermatitis - Other diseases - Other regular medicial treatment (contraceptives not included here) - Dark skin (skin type VI)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the effect of Aprepitant (Emend) on atpoic dermatitis and prutitus.;Secondary Objective: To investigate inflammatory markers in the skin during treatment with Aprepitant (Emend). ;Primary end point(s): -7 (to 9) days of treatment.;Timepoint(s) of evaluation of this end point: - The day after end of treatment (day 8 in the trial) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): -moderate-severe side effects -patient wants to stop treatment;Timepoint(s) of evaluation of this end point: Day after end of treatment period. | — |
Countries
Sweden
Contacts
Public ContactDep of dermatology, Karolinska Univ
Karolinska institutet
Outcome results
None listed